期刊文献+

地西他滨对K562/A02细胞阿霉素耐药性的影响 被引量:1

Effect of decitabine on resistance of K562/A02 cells to adriamycin
下载PDF
导出
摘要 目的:观察地西他滨(DAC)对人慢性粒细胞白血病耐药细胞株K562/A02阿霉素(ADR)耐药性的影响,探讨其作用的可能机制。方法:分别或联合应用不同浓度ADR和DAC作用于K562/A02细胞和其亲本细胞株K562,采用CCK-8法检测药物细胞毒性,Sequenom Mass ARRAY系统结合比色法评价DNA甲基化程度,流式细胞术检测K562/A02细胞细胞周期分布和细胞凋亡率。结果:K562/A02细胞较K562细胞具有显著ADR耐药性,前者ADR作用24 h的IC50约为后者的50倍。而对DAC,在0.5~8μmol/L作用浓度范围内,K562/A02细胞则较K562细胞更敏感。在相同ADR作用浓度(4.31和17.24μmol/L)下,联合1μmol/L DAC处理24 h能显著提高K562/A02细胞对ADR的敏感性,细胞存活率下降(P〈0.05)。DAC和ADR均能影响K562/A02细胞的细胞周期进程和细胞凋亡率。1μmol/L DAC的影响与作用时间相关,在作用24 h时以S期阻滞与细胞早期凋亡率升高为主,48 h时以G2/M期阻滞与细胞晚期凋亡和坏死率升高为主。ADR则主要表现为浓度依赖性G2/M期阻滞并诱导细胞晚期凋亡和坏死。两者联用使ADR对细胞周期分布的作用进一步加强,即表现为G2/M期阻滞更加明显,但对细胞凋亡率的影响并无显著差异。而在基因组甲基化程度上,2种细胞没有显著差异,DAC作用前后也没有显著改变。结论:DAC能增强K562/A02细胞对ADR的敏感性,具有逆转耐药作用,其机制可能与调节K562/A02细胞细胞周期进程、促进细胞凋亡和坏死有关。 AIM: To investigate the effect of decitabine( DAC) on the resistance of human chronic myeloid leukemia cell line K562 / A02 to adriamycin( ADR),and to explore the possible mechanism. METHODS: The K562 /A02 cell line and its parental cell line K562 were treated with different concentrations of ADR or DAC alone,or in combination. The cytotoxic effects of these 2 agents were determined by CCK-8 assay. The degree of DNA methylation was evaluated by Sequenom Mass ARRAY system and colorimetric method. The cell cycle distribution and the apoptotic rate were determined by flow cytometry. RESULTS: K562 / A02 cells were more significantly resistant to ADR than K562 cells. The half maximal inhibitory concentration of ADR for 24 h of the K562 / A02 cells was about 50 times higher than that of the K562 cells. To DAC,in the concentration range of 0. 5 ~ 8 μmol / L,K562 / A02 cells were more sensitive than K562 cells.As compared with the same concentrations( 4. 31 μmol / L and 17. 24 μmol / L) of ADR alone,the combination with 1μmol / L DAC significantly improved the sensitivity of K562 /A02 cells to ADR. Both DAC and ADR affected the cell cycle progression and apoptotic rate of K562 / A02 cells. DAC( 1 μmol / L) treatment mainly showed S phase arrest and increased early apoptotic rate for 24 h,and G2/ M phase arrest and increased late apoptosis and necrosis for 48 h in a time-related manner. ADR treatment showed G2/ M phase arrest and increased late apoptosis and necrosis in a concentration-dependent manner. In combination with 1 μmol / L DAC,the effect of ADR on the cell cycle distribution was further enhanced,showing more obvious G2/ M phase arrest,but no significant difference of the apoptotic rate was observed. The degree of methylation in the genome had no significant difference between the 2 cells,and it before and after DAC treatment had no significant change. CONCLUSION: DAC enhances the sensitivity of K562 / A02 cells to ADR,showing drug resistancereversing potential. The mechanism may be related to regulating cell cycle progression and promoting apoptosis and necrosis of K562 / A02 cells.
作者 熊鸣 王立新
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2016年第1期69-75,共7页 Chinese Journal of Pathophysiology
基金 国家自然科学基金专项基金资助项目(No.81350004) 海军总医院创新培育基金资助项目(No.cxpy201302)
关键词 地西他滨 阿霉素 K562/A02细胞 耐药性 Decitabine Adriamycin K562 /A02 cells Drug resistance
  • 相关文献

参考文献14

  • 1Gnyszka A, Jastrzebski Z, Flis S. DNA methyhransferase inhibitors and their emerging role in epigenetic therapy of cancer[ J]. Anticancer Res, 2013, 33 (8) :2989-2996.
  • 2Charlet J, Sehnekenburger M, Brown KW, et al. DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs [ J ]. Biochem Pharmacol, 2012, 83(7) :858-865.
  • 3Hackanson B, Daskalakis M. Decitabine[ J]. Recent Re- sults Cancer Res, 2014, 201:269-297.
  • 4Kurimoto M, Matsuoka H, Hanaoka N, et al. Pretreat- ment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin [ J ]. Leukemia, 2013, 27( 1 ) :233-235.
  • 5Nie J, Liu L, Li X, et al. Decitabine, a new star in epi- genetic therapy the clinical application and biologicalmechanism in solid tumors [ J~. Cancer Lett, 2014, 354 (1) : 12-20.
  • 6Mompader RL, C6t6 S, Eliopoulos N. Pharmacological approach for optimization of the dose schedule of 5-Aza- 2' -deoxyeytidine (Deeitabine) for the therapy of leukemia [J]. Leukemia, 1997, 11(2) :175-180.
  • 7Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy E J 1- Oneogene, 2002, 21 ( 35 ) :5483-5495.
  • 8Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia E J ]. Leukemia, 2013, 27 ( 9 ) : 1803- 1812.
  • 9Mirza S, Sharma G, Pandya P, et al. Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents E J 1- Mol Cell Biochem, 2010, 342(1-2) :101-109.
  • 10Xin H, Kong Y, Jiang X, et al. Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by doxorubi- cin possess tumor-initiating-cell properties [ J 1. J Pharma- col Sci, 2013, 122(4) :299-304.

二级参考文献11

共引文献5

同被引文献2

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部